LIVIVO - Search results -

Search results

Result 1 - 10 of total 154

Search options

Article: EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.

Sherman, Steven I

Transactions of the American Clinical and Climatological Association

2019 Volume 130, Page(s) 255–265

Abstract: Although treatment options for patients with advanced and metastatic thyroid carcinoma were historically limited, developments in the past 15 years in understanding the pathogenesis of these malignancies have permitted identification of novel targeted ... ...

Abstract	Although treatment options for patients with advanced and metastatic thyroid carcinoma were historically limited, developments in the past 15 years in understanding the pathogenesis of these malignancies have permitted identification of novel targeted therapies to improve outcomes. Five individual drugs and one combination therapy have achieved regulatory approval since 2011, all showing improvements in progression-free survival or high response rates. More selective targeting of mutated oncogenic kinases is leading to increasing efficacy with fewer toxicities, at least in early human trials. Collaborations among endocrinologists, medical oncologists, and patients are making advances possible, where such developments appeared impossible merely 15 years ago.
MeSH term(s)	Adenocarcinoma, Follicular/drug therapy ; Adenocarcinoma, Follicular/genetics ; Adenoma, Oxyphilic/drug therapy ; Adenoma, Oxyphilic/genetics ; Carcinoma, Neuroendocrine/drug therapy ; Carcinoma, Neuroendocrine/genetics ; Humans ; Iodine Radioisotopes/therapeutic use ; Molecular Targeted Therapy ; Protein Kinase Inhibitors/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins c-ret/genetics ; Thyroid Cancer, Papillary/drug therapy ; Thyroid Cancer, Papillary/genetics ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/genetics ; Thyroidectomy
Chemical Substances	Iodine Radioisotopes ; Protein Kinase Inhibitors ; Proto-Oncogene Proteins c-ret (EC 2.7.10.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
Language	English
Publishing date	2019-09-12
Publishing country	United States
Document type	Journal Article
ZDB-ID	603823-2
ISSN	0065-7778
ISSN	0065-7778
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 4: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Redifferentiation Therapy-Returning to Our Roots in a Post-Kinase Inhibitor World.

Cabanillas, Maria E / Busaidy, Naifa L / Sherman, Steven I

Clinical cancer research : an official journal of the American Association for Cancer Research

2022 Volume 28, Issue 19, Page(s) 4164–4166

Abstract: Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory. Using targeted drugs to reinduce RAI sensitivity ("redifferentiation therapy") has long been sought after as the ... ...

Abstract	Radioactive iodine (RAI) treatment is an effective treatment for differentiated thyroid cancer (DTC); however, many patients are refractory. Using targeted drugs to reinduce RAI sensitivity ("redifferentiation therapy") has long been sought after as the holy grail in endocrine oncology. See related article by Weber et al., p. 4194.
MeSH term(s)	Adenocarcinoma/drug therapy ; Humans ; Iodine Radioisotopes/therapeutic use ; Prospective Studies ; Protein Kinase Inhibitors/therapeutic use ; Thyroid Neoplasms/drug therapy
Chemical Substances	Iodine Radioisotopes ; Protein Kinase Inhibitors
Language	English
Publishing date	2022-08-06
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	1225457-5
ISSN	1557-3265 ; 1078-0432
ISSN (online)	1557-3265
ISSN	1078-0432
DOI	10.1158/1078-0432.CCR-22-1710
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4223: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Molecular mechanisms in thyroid cancer biology.

Sherman, Steven I

Clinical advances in hematology ; & ; oncology : H ; & ; O

2014 Volume 12, Issue 7 Suppl 14, Page(s) 10–13

Language	English
Publishing date	2014-07
Publishing country	United States
Document type	Journal Article
ZDB-ID	2271951-9
ISSN	1543-0790
ISSN	1543-0790
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6505: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer.

Weitzman, Steven P / Sherman, Steven I

Endocrinology and metabolism clinics of North America

2018 Volume 48, Issue 1, Page(s) 253–268

Abstract: Systemic therapy options have emerged for treatment of progressive, radioiodine-refractory differentiated thyroid carcinoma. Approved therapies that target tumor angiogenesis, lenvatinib and sorafenib, improve progression-free survival and, in an older ... ...

Abstract	Systemic therapy options have emerged for treatment of progressive, radioiodine-refractory differentiated thyroid carcinoma. Approved therapies that target tumor angiogenesis, lenvatinib and sorafenib, improve progression-free survival and, in an older subset, lenvatinib can prolong overall survival. Treatments based on targeting specific somatic genetic alterations are also available, which potentially also may prolong progression-free survival but are not yet approved for use by the Food and Drug Administration for this specific disease. More novel approaches that may benefit select patients include resensitization therapies that allow further radioiodine utilization and new immunotherapy concepts.
MeSH term(s)	Disease Progression ; Genetic Therapy/methods ; Humans ; Immunotherapy/methods ; Protein Kinase Inhibitors/therapeutic use ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/therapy
Chemical Substances	Protein Kinase Inhibitors
Language	English
Publishing date	2018-12-11
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	92116-6
ISSN	1558-4410 ; 0889-8529
ISSN (online)	1558-4410
ISSN	0889-8529
DOI	10.1016/j.ecl.2018.10.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Se 148: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer.

Sherman, Steven I

Oral oncology

2013 Volume 49, Issue 7, Page(s) 707–710

Abstract: Objectives: To review studies of novel multitargeted kinase inhibitors studied in patients with medullary thyroid cancer (MTC).: Materials and methods: Search of relevant references in PubMed and Google Scholar on "chemotherapy" and "medullary ... ...

Abstract	Objectives: To review studies of novel multitargeted kinase inhibitors studied in patients with medullary thyroid cancer (MTC). Materials and methods: Search of relevant references in PubMed and Google Scholar on "chemotherapy" and "medullary thyroid cancer". Results: Multitargeted kinase inhibitors have revolutionized the role of chemotherapy for progressive MTC, providing for the first time tolerable therapeutic options that can improve outcomes in patients with progressive disease. Drugs thought to inhibit the RET kinase have advanced the furthest for this disease, but these agents also target the VEGF receptor along with other kinases that may be relevant to both beneficial and adverse effects. Vandetanib improved progression-free survival from 19.3 to 30.5 months compared with placebo in patients with metastatic disease, whereas cabozantinib improved progression-free survival from 4.0 months to 11.2 months in a population with more aggressive disease. However, ''cure'' remains elusive, adverse events frequent, and exactly how such ''targeted'' agents actually function within MTC remains unclear. Conclusions: New approaches to clinical trial design and the preclinical development of targeted agents may be required to optimize the combination of maximum efficacy with minimal toxicity for patients with metastatic MTC.
MeSH term(s)	Antineoplastic Agents/therapeutic use ; Carcinoma, Neuroendocrine ; Disease-Free Survival ; Humans ; Protein Kinase Inhibitors/therapeutic use ; Thyroid Neoplasms/drug therapy
Chemical Substances	Antineoplastic Agents ; Protein Kinase Inhibitors
Language	English
Publishing date	2013-07
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1120465-5
ISSN	1879-0593 ; 0964-1955 ; 1368-8375
ISSN (online)	1879-0593
ISSN	0964-1955 ; 1368-8375
DOI	10.1016/j.oraloncology.2013.03.442
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 4869: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Challenges in the care of patients with RET-altered thyroid cancer: a multicountry mixed-methods study.

Murray, Suzanne / Subbiah, Vivek / Sherman, Steven I / Péloquin, Sophie / Sireci, Anthony / Grohé, Christian / Bubach, Patrick / Lazure, Patrice

Thyroid research

2023 Volume 16, Issue 1, Page(s) 22

Abstract: Background: The discovery of driver oncogenes for thyroid carcinomas and the identification of genomically targeted therapies to inhibit those oncogenes have altered the treatment algorithm in thyroid cancer (TC), while germline testing for RET ... ...

Abstract	Background: The discovery of driver oncogenes for thyroid carcinomas and the identification of genomically targeted therapies to inhibit those oncogenes have altered the treatment algorithm in thyroid cancer (TC), while germline testing for RET mutations has become indicated for patients with a family history of RET gene mutations or hereditary medullary TC (MTC). In the context of an increasing number of selective RET inhibitors approved for use, this paper aims to describe challenges and barriers affecting providers' ability to deliver optimal care for patients with RET-altered TC across the patient healthcare journey. Methods: A mixed-method educational and behavioral needs assessment was conducted in Germany (GER), Japan (JPN), the United Kingdom (UK), and the United States (US) prior to RET-selective inhibitor approval. Participants included medical oncologists (MO), endocrinologists (EN) and clinical pathologists (CP) caring for patients affected with TC. Data collection tools were implemented in three languages (English, German, Japanese). Qualitative data were coded and thematically analyzed in NVivo. Quantitative data were analyzed via frequency and crosstabulations in SPSS. The findings presented here were part of a broader study that also investigated lung cancer challenges and included pulmonologists. Results: A total of 44 interviews and 378 surveys were completed. Suboptimal knowledge and skills were self-identified among providers, affecting (1) assessment of genetic risk factors (56%, 159/285 of MOs and ENs), (2) selection of appropriate genetic biomarkers (59%, 53/90 of CPs), (3) treatment plan initiation (65%, 173/275 of MOs and ENs), (4) management of side effects associated with multitargeted tyrosine kinase inhibitors (78%, 116/149 of MOs and ENs), and (5) transfer of patients into palliative care services (58%, 160/274 of MOs and ENs). Interviews underscored the presence of systemic barriers affecting the use of RET molecular tests and selective inhibitors, in addition to suboptimal knowledge and skills necessary to manage the safety and efficacy of targeted therapies. Conclusion: This study describes concrete educational needs for providers involved in the care of patients with RET-altered thyroid carcinomas. Findings can be used to inform the design of evidence-based education and performance improvement interventions in the field and support integration into practice of newly approved RET-selective inhibitors.
Language	English
Publishing date	2023-08-14
Publishing country	England
Document type	Journal Article
ZDB-ID	2454440-1
ISSN	1756-6614
ISSN	1756-6614
DOI	10.1186/s13044-023-00166-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.

Lazure, Patrice / Sireci, Anthony / Subbiah, Vivek / Murray, Suzanne / Grohé, Christian / Sherman, Steven I / Kelly, Elizabeth / Bubach, Patrick / Péloquin, Sophie

BMC medical education

2023 Volume 23, Issue 1, Page(s) 410

Abstract: Background: The introduction of new targeted therapies for RET-altered lung and thyroid cancers (LC/TC) has impacted pathologists' practice by making genomic testing more relevant. Variations in health systems and treatment access result in distinct ... ...

Abstract	Background: The introduction of new targeted therapies for RET-altered lung and thyroid cancers (LC/TC) has impacted pathologists' practice by making genomic testing more relevant. Variations in health systems and treatment access result in distinct clinical challenges and barriers. This study aimed to assess practice gaps and challenges experienced by pathologists involved in the diagnosis of RET-altered LC/TC, including biomarker testing, to inform educational solutions. Methods: Pathologists in Germany, Japan, the UK, and US participated in this ethics-approved mixed-methods study, which included interviews and surveys (data collected January-March 2020). Qualitative data was thematically analysed, quantitative data was analysed with chi-square and Kruskal-Wallis H-tests, and both were triangulated. Results: A total of 107 pathologists took part in this study. Knowledge gaps were reported regarding genomic testing for LC/TC in Japan (79/60%), the UK (73/66%), and the US (53/30%). Skill gaps were reported when selecting genomic biomarker tests to diagnose TC in Japan (79%), the UK (73%) and US (57%) and when performing specific biomarker tests, especially in Japan (82% for RET) and in the UK (75% for RET). Japanese participants (80%) reported uncertainty about what information to share with the multidisciplinary team to ensure optimal patient-centered care. At the time of data collection, pathologists in Japan faced access barriers to using RET biomarker tests: only 28% agreed that there are relevant RET genomic biomarker tests available in Japan, versus 67% to 90% in other countries. Conclusions: This study identified areas where pathologists need additional continuing professional development opportunities to enhance their competencies and better support delivery of care to patients with RET-altered lung or thyroid tumours. Addressing identified gaps and improving competencies of pathologists in this field should be emphasised in continuing medical education curricula and through quality improvement initiatives. Strategies deployed on an institutional and health system level should aim to improve interprofessional communication and genetic biomarker testing expertise.
MeSH term(s)	Humans ; Thyroid Neoplasms/diagnosis ; Thyroid Neoplasms/genetics ; Thyroid Neoplasms/therapy ; Genetic Testing ; Curriculum ; Biomarkers ; Lung ; Proto-Oncogene Proteins c-ret/genetics
Chemical Substances	Biomarkers ; RET protein, human (EC 2.7.10.1) ; Proto-Oncogene Proteins c-ret (EC 2.7.10.1)
Language	English
Publishing date	2023-06-05
Publishing country	England
Document type	Journal Article
ZDB-ID	2044473-4
ISSN	1472-6920 ; 1472-6920
ISSN (online)	1472-6920
ISSN	1472-6920
DOI	10.1186/s12909-023-04396-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Emerging treatments in thyroid cancer.

Sherman, Steven I

Clinical advances in hematology & oncology : H&O

2012 Volume 10, Issue 9, Page(s) 594–596

MeSH term(s)	Biomarkers, Tumor ; Humans ; Thyroid Neoplasms/therapy
Chemical Substances	Biomarkers, Tumor
Language	English
Publishing date	2012-09
Publishing country	United States
Document type	Journal Article
ZDB-ID	2271951-9
ISSN	1543-0790
ISSN	1543-0790
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6505: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Targeted therapies for thyroid tumors.

Sherman, Steven I

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

2011 Volume 24 Suppl 2, Page(s) S44–52

Abstract: Systemic chemotherapies for advanced or metastatic thyroid carcinomas have been of only limited effectiveness. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, novel therapies are needed to improve disease ...

Abstract	Systemic chemotherapies for advanced or metastatic thyroid carcinomas have been of only limited effectiveness. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, novel therapies are needed to improve disease outcomes. Multiple novel therapies primarily targeting angiogenesis have entered clinical trials for metastatic thyroid carcinoma. Partial response rates up to 30% have been reported in single-agent studies, but prolonged disease stabilization is more commonly observed. The most successful agents target the vascular endothelial growth factor receptors, with potential targets including the mutant kinases associated with papillary and medullary oncogenesis. Two drugs approved for other malignancies, sorafenib and sunitinib, have had promising preliminary results reported, and are being used selectively for patients who do not qualify for clinical trials. At least one randomized, placebo-controlled phase III trial has been successfully completed, showing improved progression-free survival in patients with advanced or metastatic medullary thyroid carcinoma treated with vandetanib. Randomized trials for other agents are currently underway. Treatment for patients with metastatic or advanced thyroid carcinoma now emphasizes clinical trial opportunities for novel agents with considerable promise. Alternative options now exist for use of tyrosine kinase inhibitors that are well tolerated and may prove worthy of regulatory approval for this disease.
MeSH term(s)	Adenocarcinoma, Follicular/drug therapy ; Adenocarcinoma, Follicular/secondary ; Adenocarcinoma, Papillary/drug therapy ; Adenocarcinoma, Papillary/secondary ; Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase III as Topic ; Molecular Targeted Therapy/methods ; Randomized Controlled Trials as Topic ; Thyroid Neoplasms/drug therapy ; Thyroid Neoplasms/pathology
Chemical Substances	Antineoplastic Agents
Language	English
Publishing date	2011-03-25
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	645073-8
ISSN	1530-0285 ; 0893-3952
ISSN (online)	1530-0285
ISSN	0893-3952
DOI	10.1038/modpathol.2010.165
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2450: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer.

Sherman, Steven I

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

2011 Volume 19, Issue 1, Page(s) 157–161

Abstract: Objective: To describe the evolving role of recombinant human thyrotropin in the diagnostic evaluation of patients treated for differentiated thyroid carcinoma.: Methods: A systematic review was performed of published English language articles ... ...

Abstract	Objective: To describe the evolving role of recombinant human thyrotropin in the diagnostic evaluation of patients treated for differentiated thyroid carcinoma. Methods: A systematic review was performed of published English language articles appearing in PubMed using terms "recombinant thyrotropin" and "thyroid cancer". The author selected articles for inclusion based upon potential for clinical impact of the reported findings. Results: The addition of recombinant human thyrotropin to diagnostic testing replaced the requirement for thyroid hormone withdrawal and symptomatic hypothyroidism that had been necessary to generate sufficient endogenous thyrotropin for radioiodine scanning and thyroglobulin testing. The high negative predictive value of stimulated thyroglobulin testing removed the need for serial radioiodine scanning for many patients, but repeated stimulated testing rarely appeared to add significantly. The development of highly sensitive second generation thyroglobulin assays may replace the need for stimulated testing in a subset of patients. Conclusion: Recombinant human thyrotropin-stimulated testing continues to be a valuable component of follow-up testing in the first year after initial treatment of differentiated thyroid cancer.
MeSH term(s)	Humans ; Iodine Radioisotopes/therapeutic use ; Radionuclide Imaging ; Thyroid Neoplasms/diagnostic imaging ; Thyroid Neoplasms/pathology ; Thyroid Neoplasms/radiotherapy ; Thyrotropin Alfa
Chemical Substances	Iodine Radioisotopes ; Thyrotropin Alfa
Language	English
Publishing date	2011-06-04
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review ; Systematic Review
ZDB-ID	1473503-9
ISSN	1934-2403 ; 1530-891X
ISSN (online)	1934-2403
ISSN	1530-891X
DOI	10.4158/EP12315.RA
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5034: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 508: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito